Biohaven Ltd. (NYSE:BHVN) Given Average Recommendation of "Moderate Buy" by Brokerages

Key Points

• Consensus: "Moderate Buy" — Seventeen brokerages cover Biohaven with an average recommendation of Moderate Buy (breakdown: 1 sell, 5 hold, 8 buy, 3 strong buy) and an average 1‑year target price of $22.43.
• Shares trade around $8.92 (50‑/200‑day SMAs $11.35/$12.21) with a market cap of ~$944.6M, a negative PE and analysts forecasting roughly -8.9 EPS for the year, highlighting continuing losses and volatility (1‑year range $7.48–$31.18).
• Institutional ownership is very high at 88.78%, with recent stake increases by firms like Invesco and new positions from HSBC, while analyst actions remain mixed—Goldman Sachs and RBC upgraded/rerated higher even as UBS and Weiss cut ratings.

Biohaven Ltd. (NYSE:BHVN - Get Free Report) has earned an average recommendation of "Moderate Buy" from the seventeen brokerages that are covering the stock, MarketBeat.com reports. One equities research analyst has rated the stock with a sell rating, five have issued a hold rating, eight have issued a buy rating and three have given a strong buy rating to the company. The average 1 year target price among brokerages that have covered the stock in the last year is $22.4286.

Several analysts have issued reports on BHVN shares. Royal Bank Of Canada boosted their price target on Biohaven from $22.00 to $23.00 and gave the company an "outperform" rating in a report on Tuesday, March 3rd. The Goldman Sachs Group raised Biohaven to a "strong-buy" rating in a research note on Friday, February 6th. Weiss Ratings reaffirmed a "sell (d-)" rating on shares of Biohaven in a research report on Monday, December 29th. Morgan Stanley lowered their price objective on Biohaven from $26.00 to $21.00 and set an "overweight" rating on the stock in a research report on Tuesday, January 6th. Finally, UBS Group lowered shares of Biohaven from a "buy" rating to a "neutral" rating and reduced their target price for the stock from $26.00 to $11.00 in a report on Wednesday, November 26th.

Biohaven Stock Down 0.4%

BHVN opened at $8.92 on Friday. The firm's 50 day simple moving average is $11.35 and its two-hundred day simple moving average is $12.21. The company has a market capitalization of $944.59 million, a PE ratio of -1.28 and a beta of 1.15. Biohaven has a 1-year low of $7.48 and a 1-year high of $31.18. The company has a current ratio of 3.18, a quick ratio of 3.18 and a debt-to-equity ratio of 4.59.

Biohaven (NYSE:BHVN - Get Free Report) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($1.21) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($1.22) by $0.01. As a group, equities analysts forecast that Biohaven will post -8.9 EPS for the current year.

Institutional Trading of Biohaven

A number of hedge funds and other institutional investors have recently modified their holdings of BHVN. Hsbc Holdings PLC bought a new stake in shares of Biohaven during the 4th quarter valued at $282,000. Caitong International Asset Management Co. Ltd purchased a new stake in Biohaven in the 4th quarter worth $81,000. Invesco Ltd. increased its stake in Biohaven by 59.0% in the 4th quarter. Invesco Ltd. now owns 194,751 shares of the company's stock worth $2,199,000 after buying an additional 72,230 shares in the last quarter. Mercer Global Advisors Inc. ADV bought a new stake in Biohaven during the fourth quarter valued at about $342,000. Finally, XTX Topco Ltd lifted its position in shares of Biohaven by 31.1% in the fourth quarter. XTX Topco Ltd now owns 83,455 shares of the company's stock valued at $942,000 after acquiring an additional 19,816 shares in the last quarter. 88.78% of the stock is owned by hedge funds and other institutional investors.

Biohaven Company Profile

Biohaven Ltd. (NYSE BHVN) is a clinical-stage biopharmaceutical company dedicated to developing and commercializing therapies for neurological and neurovascular diseases. Founded in 2013 as a spin-out from Yale University, Biohaven focuses on addressing high-unmet medical needs through innovative small-molecule and peptide-based platforms. The company is headquartered in New Haven, Connecticut, and maintains research activities across the United States, with collaborative ties in Europe and Asia via strategic partnerships.

The company's most advanced program centers on calcitonin gene-related peptide (CGRP) receptor antagonists for the acute and preventive treatment of migraine.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.